{"id":"NCT05059301","sponsor":"GlaxoSmithKline","briefTitle":"A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above","officialTitle":"A Phase 3, Randomized, Double-blind, Multi-country Study to Evaluate Consistency, Safety, and Reactogenicity of 3 Lots of RSVPreF3 OA Investigational Vaccine Administrated as a Single Dose in Adults Aged 60 Years and Above","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-10-01","primaryCompletion":"2022-01-24","completion":"2022-06-30","firstPosted":"2021-09-28","resultsPosted":"2023-02-15","lastUpdate":"2023-02-15"},"enrollment":770,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Respiratory Syncytial Virus Infections"],"interventions":[{"type":"BIOLOGICAL","name":"RSVPreF3 OA investigational vaccine","otherNames":[]}],"arms":[{"label":"RSV OA_Lot 1","type":"EXPERIMENTAL"},{"label":"RSV OA_Lot 2","type":"EXPERIMENTAL"},{"label":"RSV OA_Lot 3","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the lot-to-lot consistency in terms of immunogenicity and evaluate the safety and reactogenicity of 3 lots of the RSVPreF3 OA investigational vaccine administered as a single dose in adults â‰¥ 60 years of age (YOA).","primaryOutcome":{"measure":"RSVPreF3 Specific Immunoglobin (Ig)G Antibody Concentrations Expressed as Group Geometric Mean Concentration (GMC)","timeFrame":"At 30 days post-vaccination (Day 31)","effectByArm":[{"arm":"RSV OA_Lot 1","deltaMin":86039.9,"sd":null},{"arm":"RSV OA_Lot 2","deltaMin":80518,"sd":null},{"arm":"RSV OA_Lot 3","deltaMin":94260.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"60 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":18},"locations":{"siteCount":19,"countries":["United States","Canada","Sweden"]},"refs":{"pmids":["38746060"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":251},"commonTop":["Injection site pain","Myalgia","Fatigue","Headache","Arthralgia"]}}